CG oncology
CGON69.1204.82% ( -3.500 )
CG oncology (CGON)
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer...
- Open
- 73.310
- High
- 73.500
- Low
- 67.790
- Prev. Close
- 72.620
- Volume
- 1.10M
- Turnover
- 76.46M
- Avg Price
- 69.250
- Bid/Ask Ratio
- --
- Amplitude
- 7.86%
- 52wk High
- 77.000
- Volume Ratio
- 1.40
- Turnover Ratio
- 1.68%
CG oncology Analyst Rating
View MoreForecast & Rating
Jul 29, 2026Price forecast
$90.6931.21%
Forecast & RatingStrong buy
15analysts
- Strong buy66.67%
- Buy26.67%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 01:14 AM
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Moderate Buy" from Analysts
- StockTitan · 2 days ago, 09:45 AM
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology | CGON Stock News
- Global Report · Jul 25 at 04:14 AM
From Unbundling to Scarcity: The Limits of Aggregation in the Market's Periphery
- PUBT · Jul 17 at 03:15 PM
CG Oncology director Leonard Post disposes of 1,000 shares for $71,170
- Simplywall · Jul 14 at 08:13 PM
How CG Oncology’s Phase II Bladder Cancer Data and 2026 BLA Timeline Will Impact CGON Investors
- PUBT · Jul 14 at 03:15 PM
CG Oncology director James Mulay disposes of common shares worth $1.82 million
